RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:213504

Adenocarcinoma of ovary

high confidenceDisorder

Also known as: Ovarian adenocarcinoma

Publications

7,740

93.4th percentile

Trials

24

Interventional, condition-specific

Researchers

1,136

Distinct authors in sample

Gene link

—

Readiness

4/6

Stages with a signal

How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (4)

adenocarcinoma of ovary · adenocarcinoma of the ovary · ovarian adenocarcinoma · ovary adenocarcinoma

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

4/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    7,740 matched papers (3,760 in last 10 years) Source

  3. Phenotype characterisedPresent

    1 HPO annotations (e.g. signet ring cell carcinoma) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationPartial

    1 FDA designation (none yet with FDA orphan-indication approval) — e.g. Altretamine Source

  6. Interventional trialPresent

    24 matched on ClinicalTrials.gov (7 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

1

Associated phenotypes · MONDO:0002752

  • signet ring cell carcinoma

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

1

Designation · no FDA orphan-indication approval yet

  • FDA Altretamine (Hexalen)Adenocarcinoma of the Ovary Advanced Adenocarcinoma · 1984-02-09

Sources: FDA OOPD · EMA orphan designations

Open Targets candidates

15

Drugs / clinical candidates · MONDO_0002752

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

7,740

7,740 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

7,740 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

3,760 in the last 10 years · high confidence · 93.4th percentile (publications denominator)

Phrase hits: 7,740 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,136

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Tuncer MC8 papers · 2025

    Department of Anatomy, Faculty of Medicine, Dicle University, Diyarbakir 21280, Turkey.

    Papers in Europe PMC
  2. 02
    Özdemir İ7 papers · 2025

    Department of Histology and Embryology, Faculty of Medicine, Kahramanmaraş Sütçü İmam University, Kahramanmaraş 46100, Turkey.

    Papers in Europe PMC
  3. 03
    Öztürk Ş5 papers · 2025

    Vocational School of Health Services, Çanakkale Onsekiz Mart University, Çanakkale 17100, Turkey.

    Papers in Europe PMC
  4. 04
    Solár P5 papers · 2026

    Department of Medical Biology, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, SK-04154, Košice, Slovak Republic. Electronic address: peter.solar@upjs.sk.

    Papers in Europe PMC
  5. 05
    Solárová Z5 papers · 2026

    Department of Pharmacology, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, SK-04154, Košice, Slovak Republic.

    Papers in Europe PMC
  6. 06
    Wang Y5 papers · 2026

    Department of Medical Oncology, Affiliated Dongyang Hospital of Wenzhou Medical University Dongyang, Zhejiang, China.

    Papers in Europe PMC
  7. 07
    Bhide M4 papers · 2026

    Institute of Neuroimmunology, Slovak Academy of Sciences, Dubravska cesta 9, SK-841 04, Bratislava, Slovak Republic; Laboratory of Biomedical Microbiology and Immunology, University of Veterinary Medicine and Pharmacy in Košice, SK-04154, Košice, Slovak Republic.

    Papers in Europe PMC
  8. 08
    Harvanik P4 papers · 2026

    Department of Medical Biology, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, SK-04154, Košice, Slovak Republic.

    Papers in Europe PMC
  9. 09
    Liu Y4 papers · 2025

    Hubei Provincial Key Laboratory for Chinese Medicine Resources and Chinese Medicine Chemistry, School of Pharmacy, Hubei University of Chinese Medicine, Wuhan, China.

    Papers in Europe PMC
  10. 10
    Toprak V4 papers · 2025

    Private Metrolife Hospital, Şanlıurfa 63320, Turkey.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

24

interventional trials for this specific condition

24 interventional trials matched this specific condition name; 7 currently recruiting in our sample. 3,668 trials are registered for adenocarcinoma, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 11 September 2026

24 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 95.4th percentile).

high confidence · 95.4th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

24 interventional trials matched after quoted-phrase search and title/condition post-filter.

Broader category: adenocarcinoma

3,668

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Observational and natural-history studies

7 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 18 · after dedupe 18 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 18 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Uncertain / not reviewed (18)

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Adenocarcinoma of ovary — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Adenocarcinoma of ovary" OR "Adenocarcinoma of the ovary" OR "Ovarian adenocarcinoma" OR "ovary adenocarcinoma"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Adenocarcinoma of ovary" OR "Adenocarcinoma of the ovary" OR "Ovarian adenocarcinoma" OR "ovary adenocarcinoma"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 24 interventional · 7 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"adenocarcinoma"

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T09:33:12.576Z